Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of GLP-1 analogue in multiple sclerosis
2024-519235-42-00Phase 2Authorised
- Sponsor
- Comenius University Bratislava
- Start
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of semaglutide and dulaglutide in multiple sclerosis (MS) (2 arms), sponsored by Comenius University Bratislava. Primary endpoints: Annualized change in brain volume, Annualized change in gray matter volume and 1 more. Planned start Nov 2024; status: authorised.
02
Drugs
semaglutidedulaglutide
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2024-519235-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519235-42-00.